Candida auris outbreak: Mortality, interventions and cost of sustaining control

  25 September 2019

34 patients acquired the organism including 8 with blood stream infections. Clinical infection was significantly associated with prolonged hospital stay, haemodialysis and antifungal therapy. Variable susceptibility to amphotericin and the triazoles was seen and isolates clustered with the South Asian strains. No significant difference was detected in the survival probabilities of C .auris BSI compared to other candidemias. Outbreak control cost in excess of £ 1 million and £58,000/month during the subsequent year.

Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed